Company

NILO Therapeutics, Inc.

Nilo Therapeutics develops therapies that use neural circuits to address autoimmune and inflammatory diseases.

About

Nilo Therapeutics is developing immunomodulation therapies that target brain-body circuits involved in systemic inflammation. Its research is focused on autoimmune and inflammatory diseases. Founded in 2024 and based in New York, the company raised USD 101.00 mn in Series A funding in October 2025, co-led by The Column Group, Data Collective, and Lux Capital, with participation from Gates Family Foundation and Alexandria Venture Investments.

1Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in